Lilly to Expand Indianapolis Insulin Manufacturing Operations
$140 million investment will address growing U.S. diabetes demand
INDIANAPOLIS, Nov. 1, 2012
INDIANAPOLIS, Nov. 1, 2012 /PRNewswire/ --Local and state government
officials joined representatives from Eli Lilly and Company (NYSE: LLY) today
to announce a $140 million expansion to the company's Indianapolis insulin
manufacturing operations. The 80,000-square-foot expansion, which will enable
the manufacturing of insulin cartridges to meet the growing diabetes demand in
the U.S., represents one of the most significant investments in Lilly's
U.S.-based manufacturing operations in the past decade.
Construction will begin immediately with completion expected in March 2014.
During this period, construction trade staffing will average 250, with peak
employment at approximately 350 workers at the site. Once operational in 2015,
more than 100 full-time, highly skilled, specialized technicians, scientists,
and engineers will be needed to manage the operations.
Diabetes care is a major segment of Lilly's pharmaceutical business with
projections from health care experts – including the Centers for Disease
Control and Prevention – indicating that as many as one in three U.S. adults
could have diabetes by 2050. The rise in prevalence of the disease is due, in
part, to an aging population more likely to develop type 2 diabetes, increases
in minority populations that are at high risk for type 2 diabetes, and people
with diabetes living longer. Diabetes afflicted 366 million people worldwide
last year, according to the International Diabetes Federation.
John C. Lechleiter, Ph.D., Lilly's chairman, president, and chief executive
officer, said that Lilly's commitment to meeting the long-term needs of people
with diabetes in the U.S., as well as its role as a biomedical leader in
Indiana, drove the company's decision to build this state-of-the-art
manufacturing facility in Indianapolis.
"Lilly is committed to providing a full range of innovative treatment options
for people with diabetes," said Lechleiter. "The need in our country is great
– and it is growing. This investment will help us to better meet that need
while expanding our advanced manufacturing footprint in our home state –
helping to strengthen Indiana's bioscience industry."
Lechleiter said the new facility will manufacture insulin cartridges for
people with diabetes. It will be a first-of-its-kind facility for Lilly in the
Lilly's reorganization of its diabetes operations almost three years ago has
provided greater focus on its innovation-based product portfolio and pipeline
of potential new medicines. Today, the company has 10 potential new diabetes
medicines in various stages of clinical development including oral
medications, insulins, and a once-a-week treatment to meet the needs of people
Lilly's $140 million expansion is one of the largest economic development
investments in both the city and state in 2012.
"Lilly is the premier pharmaceutical company in the world and their commitment
to research keeps them ahead of the medical curve," said Lt. Governor Becky
Skillman. "This expansion is just further proof that Indiana is a fiscally
strong state, and we thank Lilly for their confidence in our state and our
"Lilly's expansion brings new jobs and investment of new capital to our local
economy, demonstrating the company's confidence in doing business in
Indianapolis and strengthening our advanced manufacturing and bioscience
industries," said Indianapolis Mayor Greg Ballard. "We are pleased to see this
industry leader that calls Indianapolis home continuing along its growth path,
which is good for our community and the Central Indiana region as a whole."
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
Contact: Edward Sagebiel, +1-317-433-9899, email@example.com, or Greg Kueterman,
Press spacebar to pause and continue. Press esc to stop.